Advance your research, with stronger evidence
From identifying the unanswered questions to building study rationales, protocols and publications, Causaly helps you find, synthesize and verify scientific evidence in a fraction of the time.
Your research is never used to train models. ISO 27001 certified.
The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02).
Trusted by research teams at leading biopharma companies. Now open to clinician-researchers.
Four questions every study has to answer
A clinical research fellow shaping a first fellowship application, a hospital research team drafting a protocol, a guideline panel weighing the trials: each has to show reviewers what is already known before anyone funds, approves or follows the work. That case rests on four questions, and a reviewer will check every answer.
Below, one real study idea taken through all four: low-dose colchicine after a heart attack.
- 1Is the question still open?What has been published, what is registered and running, and where nothing exists yet.
- 2Why is the study needed?Where earlier trials disagree, and why: the case for a new one.
- 3How should it be designed?The doses, endpoints, event rates and safety signals earlier trials used.
- 4Will the references hold up?Every claim in your draft, one click from the sentence it came from.
Know where the gap is before you write
Published trials, registered and ongoing trials, and the populations no one has tested yet, in one answer. Funders ask for exactly this.
The gap: no completed trial restricted to adults over 75, and none in chronic kidney disease or dialysis, where only trials still running are registered.
Make the case: where the trials disagree, and why
Conflicting trials are the reason a new one is needed. Causaly sets them side by side and explains the differences in population, timing and dose, each with its source.
Started within 72 hours of PCI, in a mostly STEMI population. Commentators suggest the hyper-acute phase may respond differently from the weeks after MI, where COLCOT saw benefit.
● Laudani et al., 2025Effect estimates as reported by each trial for its own primary endpoint. Endpoints differ between trials; this is not a meta-analysis.
Design it on what earlier trials did
The doses, timing, endpoints, event rates and safety signals of every earlier trial, side by side, so each choice in your protocol starts from evidence.
The doses, timing and endpoints earlier trials chose, side by side.
| Trial | Regimen | Started | Primary endpoint |
|---|---|---|---|
| COLCOT | 0.5 mg daily vs placebo | Within 30 days of MI (mean 13.5 days) | CV death, arrest, MI, stroke, urgent angina revascularization1 |
| CLEAR SYNERGY | Colchicine vs placebo, 2×2 with spironolactone | Within 72 h of PCI | CV death, MI, stroke, ischemia-driven revascularization2 |
| COPS | 0.5 mg twice daily for a month, then daily | During the ACS admission | Death, ACS, urgent revascularization, stroke3 |
| LoDoCo-MI | 0.5 mg daily vs placebo | Within 7 days of MI | hs-CRP ≥2 mg/L at 30 days4 |
Every claim, one click from its sentence
Before a reviewer, a co-author or an ethics committee asks where a number came from. Every claim opens on the passage it rests on, every search is on record, and the references export with their full metadata.
In randomized trials, low-dose colchicine reduced cardiovascular events after a recent myocardial infarction1 and in chronic coronary disease2, but the largest trial, started within 72 hours of PCI, found no reduction3. Whether timing explains the difference is unresolved.
The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02).
- Every search on recordRerun any search to see its full result set
- Screened and referencedSee every document it read, and the ones it cited
- References exportedAuthors, journal, dates, publication type and MeSH terms
Pick a question and run it
“It provided multiple up-to-date articles and a table — exactly what I needed.”
“I like the fact that you see the reasoning, so you understand how it goes through all the information.”
The literature and the trial registries, searched in one question
Built for science, measured against general AI
Same research questions, three tools. Causaly finds more of the evidence that matters and cites nothing off-topic.
vs. 42% for ChatGPT and 20% for Claude
with 100% groundedness in the evaluation
vs. 7% for ChatGPT and 30% for Claude
Your study ideas stay private
- Never used to train models
- Visible only to the people you share a workspace with
- Encrypted in transit and at rest
- ISO 27001 certified
Start your next study with the evidence in hand.
Get started on your own questions today.
Start your free trialFor research, literature review and evidence synthesis. Not for diagnosis or decisions about individual patients.